Bendamustine plus mitoxantrone for relapsed/refractory chronic lymphocytic leukaemia (CLL): Results of a multicentre phase II study of the German CLL Study Group (GCLLSG)

British Journal of Haematology

Volumn 158, Issue 2, 2012, Pages 238-241

  Köppler, Hubert ^a   Fuss, Harald ^b   Hurtz, Hans J ^c   Knigge, Owe ^d   Losem, Christoph ^e   Reschke, Daniel ^f   Schmitz, Stephan ^g   Weide, Rudolf ^a   Weiß, Johann ^h   Hallek, Michael ⁱ  

^a Haematology/Oncology Group Practice   (Germany)

^b HELIOS Klinikum Bad Saarow   (Germany)

^c Haematology/Oncology Group Practice   (Germany)

^d Haematology/Oncology Practice ^*  (Germany)

^e Haematology/Oncology Group Practice   (Germany)

^f Haematology/Oncology Group Practice   (Germany)

^g Haematology/Oncology Group Practice   (Germany)

^h Haematology/Oncology Practice   (Germany)

ⁱ UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Clinical studies; CLL; Drugs; Leukaemia therapy

Indexed keywords

BENDAMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; MITOXANTRONE; PREDNISOLONE; VINCRISTINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CHRONIC LYMPHATIC LEUKEMIA; CREATININE BLOOD LEVEL; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG EFFICACY; FEMALE; HUMAN; HYPERURICEMIA; INFECTION; LEUKEMIA RELAPSE; LEUKOCYTE COUNT; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; REFRACTORY B CELL CHRONIC LYMPHATIC LEUKEMIA; RELAPSED B CELL CHRONIC LYMPHATIC LEUKEMIA; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MITOXANTRONE; NITROGEN MUSTARD COMPOUNDS; RECURRENCE; TREATMENT OUTCOME;

EID: 84863422856     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2012.09132.x     Document Type: Article

References (15)

1. A'Hern, R.P. (2001) Sample size tables for exact single-stage phase II designs. Statistics in Medicine, 20, 859-866.
2. Badoux, X.C., Keating, M.J., Wang, X., O'Brien, S.M., Ferrajoli, A., Faderl, S., Burger, J., Koller, C., Lerner, S., Kantarjian, H. & Wierda, W.G. (2011) Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood, 117, 3016-3024.
3. Bergmann, M.A., Goebeler, M.E., Herold, M., Emmerich, B., Wilhelm, M., Ruelfs, C., Boening, L. & Hallek, M.J. (2005) Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group. Haematologica, 90, 1357-1364.
4. Bremer, K. (2002) High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas. Journal of Cancer Research Clincal Oncology, 128, 603-609.
5. Cheson, B.D., Bennett, J.M., Grever, M., Kay, N., Keating, M.J., O'Brien, S. & Rai, K.R. (1996) National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood, 87, 4990-4997.
6. Hallek, M., Schmitt, B., Wilhelm, M., Busch, R., Krober, A., Fostitsch, H.P., Sezer, O., Herold, M., Knauf, W., Wendtner, C.M., Kuse, R., Freund, M., Franke, A., Schriever, F., Nerl, C., Dohner, H., Thiel, E., Hiddemann, W., Brittinger, G. & Emmerich, B. (2001) Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group. British Journal of Haematology, 114, 342-348.
7. Hendry, L., Bowen, A., Matutes, E., Swansbury, J. & Catovsky, D. (2004) Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma. Leukemia Lymphoma, 45, 945-950.
8. Kath, R., Blumenstengel, K., Fricke, H.J. & Hoffken, K. (2001) Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. Journal of Cancer Research Clincal Oncology, 127, 48-54.
9. Knauf, W.U., Lissichkov, T., Aldaoud, A., Liberati, A., Loscertales, J., Herbrecht, R., Juliusson, G., Postner, G., Gercheva, L., Goranov, S., Becker, M., Fricke, H.J., Huguet, F., Del, G.I., Klein, P., Tremmel, L., Merkle, K. & Montillo, M. (2009) Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. Journal of Clincal Oncology, 27, 4378-4384.
10. Koppler, H., Heymanns, J., Pandorf, A. & Weide, R. (2004) Bendamustine plus mitoxantrone-a new effective treatment for advanced chronic lymphocytic leukaemia: results of a phase I/II study. Leukemia Lymphoma, 45, 911-913.
11. O'Brien, S., Moore, J.O., Boyd, T.E., Larratt, L.M., Skotnicki, A.B., Koziner, B., Chanan-Khan, A.A., Seymour, J.F., Gribben, J., Itri, L.M. & Rai, K.R. (2009) 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. Journal of Clincal Oncology, 27, 5208-5212.
12. Ozegowski, W. & Krebs, D. (1971) "IMET 3393, gamma-(1-Methyl-5-bis-(β-chloräthyl)-amino-benzimidazolyl(2))-buttersäure-hydrochlorid, ein neues Zytostatikum aus der Reihe der Benzimidazol-Loste". Zentralblatt Pharmacokinetics, 110, 1013-1019.
13. Rai, R.K., Peterson, B.L., Appelbaum, F.R., Kolitz, J., Elias, L., Shepherd, L., Hines, J., Threatte, G.A., Larson, R.A., Cheson, B.D. & Schiffer, C.A. (2000) "Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia". New England Journal of Medicine, 343, 1750-1757.
14. Schiavone, E.M., De, S.M., Palmieri, S., Annunziata, M., Pocali, B., Copia, C., D'Amico, M.R., Vecchio, L.D. & Ferrara, F. (2003) Fludarabine plus cyclophosphamide for the treatment of advanced chronic lymphocytic leukemia. European Journal of Haematology, 71, 23-28.
15. Weide, R., Heymanns, J., Gores, A. & Koppler, H. (2002) Bendamustine mitoxantrone and rituximab (BMR): a new effective regimen for refractory or relapsed indolent lymphomas. Leukemia Lymphoma, 43, 327-331.